Forsta AP Fonden Sells 6,200 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Forsta AP Fonden decreased its position in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 31.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,800 shares of the biotechnology company’s stock after selling 6,200 shares during the quarter. Forsta AP Fonden’s holdings in Axon Enterprise were worth $4,061,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blue Trust Inc. grew its position in shares of Axon Enterprise by 987.5% during the 2nd quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after buying an additional 79 shares in the last quarter. ICA Group Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 4th quarter worth $26,000. Trivant Custom Portfolio Group LLC purchased a new stake in shares of Axon Enterprise during the 1st quarter worth $31,000. First PREMIER Bank purchased a new stake in shares of Axon Enterprise during the 1st quarter worth $33,000. Finally, Blue Bell Private Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 1st quarter worth $41,000. Institutional investors own 79.08% of the company’s stock.

Insider Activity

In other news, CFO Brittany Bagley sold 4,338 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now owns 98,825 shares in the company, valued at $37,449,733.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $373.03, for a total transaction of $167,863.50. Following the transaction, the director now owns 7,379 shares in the company, valued at $2,752,588.37. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brittany Bagley sold 4,338 shares of Axon Enterprise stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total value of $1,643,885.10. Following the transaction, the chief financial officer now owns 98,825 shares in the company, valued at approximately $37,449,733.75. The disclosure for this sale can be found here. Insiders have sold a total of 316,981 shares of company stock worth $115,281,744 over the last quarter. 6.10% of the stock is currently owned by corporate insiders.

Axon Enterprise Stock Down 1.3 %

Shares of AXON opened at $379.61 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 12 month low of $189.12 and a 12 month high of $385.00. The stock’s 50 day moving average is $338.92 and its two-hundred day moving average is $314.65. The firm has a market cap of $28.69 billion, a P/E ratio of 111.00, a PEG ratio of 10.30 and a beta of 0.94.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The company had revenue of $504.00 million for the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. Axon Enterprise’s quarterly revenue was up 34.5% compared to the same quarter last year. During the same period last year, the company earned $0.80 earnings per share. Analysts predict that Axon Enterprise, Inc. will post 1.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AXON shares. Needham & Company LLC restated a “buy” rating and set a $400.00 price objective on shares of Axon Enterprise in a research note on Wednesday, August 7th. Northland Securities increased their price target on Axon Enterprise from $330.00 to $365.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Bank of America began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price target for the company. Craig Hallum increased their price objective on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, Robert W. Baird increased their price objective on Axon Enterprise from $360.00 to $400.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average price target of $365.38.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.